Market Place
Sourcing Support
Roche`s Prothena-partnered Parkinson`s prospect fails phase 2b
19 Dec 2024 //
FIERCE BIOTECH
Roche’s Prothena-partnered Parkinson’s prospect fails phase 2b
19 Dec 2024 //
FIERCE BIOTECH
Prothena Reports Q3 2024 Financial Results and Business Highlights
12 Nov 2024 //
BUSINESSWIRE
Prothena to Report Q3 2024 Financial Results on November 12
05 Nov 2024 //
BUSINESSWIRE
Prothena Announces Leadership Team Updates
27 Sep 2024 //
BUSINESSWIRE
Prothena to Participate in Upcoming Healthcare Conferences
29 Aug 2024 //
BUSINESSWIRE
Prothena Reports Second Quarter 2024 Financial Results and Business Highlights
08 Aug 2024 //
BUSINESSWIRE
Prothena to Report Second Quarter 2024 Financial Results on August 8
01 Aug 2024 //
BUSINESSWIRE
Prothena: BMS Option For Second Neuroscience Drug Candidate PRX019
28 May 2024 //
BUSINESSWIRE
Prothena Reports First Quarter 2024 Financial Results and Business Highlights
08 May 2024 //
BUSINESSWIRE
Prothena to Report First Quarter 2024 Financial Results on May 8
01 May 2024 //
BUSINESSWIRE
Prothena: Birtamimab Review Published In Leukemia & Lymphoma
15 Apr 2024 //
BUSINESSWIRE
Prothena to Participate in Upcoming Healthcare Conferences
05 Mar 2024 //
BUSINESSWIRE
Prothena Appoints David Ford to Newly Created Chief People Officer Position
04 Mar 2024 //
BUSINESSWIRE
Prothena Announces Appointment of Daniel G. Welch as Director & Chair Designate
21 Feb 2024 //
BUSINESSWIRE
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results
15 Feb 2024 //
PRESS RELEASE
Prothena to Report Fourth Quarter and Full Year 2023 Financial Results
08 Feb 2024 //
BUSINESSWIRE
Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs
08 Jan 2024 //
PRESS RELEASE
Prothena Reports Third Quarter 2023 Financial Results and Business Highlights
02 Nov 2023 //
BUSINESSWIRE
Prothena to Report Third Quarter 2023 Financial Results on November 2
26 Oct 2023 //
BUSINESSWIRE
Biotech Firm Prothena Is Said to Prepare for Potential Sale
16 Oct 2023 //
BLOOMBERG
Prothena prepares for potential sale - Bloomberg News
16 Oct 2023 //
REUTERS
Prothena to Participate in Upcoming Healthcare Conferences
31 Aug 2023 //
BUSINESSWIRE
Prothena Reports Second Quarter 2023 Financial Results and Business Highlights
03 Aug 2023 //
PRESS RELEASE
Prothena to Report Second Quarter 2023 Financial Results on August 3
27 Jul 2023 //
PRESS RELEASE
Prothena Presents New Research in the Treatment of Alzheimer’s Disease at AAI
17 Jul 2023 //
BUSINESSWIRE
Prothena to Present New Data from Alzheimer’s Disease Programs at AAIC
11 Jul 2023 //
BUSINESSWIRE
Prothena Announces BMS Opt-in for Worldwide Rights of PRX005
11 Jul 2023 //
YAHOO FINANCE
Prothena Announces Ph 3 VITAL Trial Blood Showing Benefit IV AL Treat Birtamimab
27 Jun 2023 //
BUSINESSWIRE
Prothena to Participate in Jefferies 2023 Healthcare Conference
02 Jun 2023 //
BUSINESSWIRE
Billy Dunn’s Prothena Board Position Reignites Ethical Debate
23 May 2023 //
BIOSPACE
Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors
16 May 2023 //
BUSINESSWIRE
Prothena Analysts Just Trimmed Their Revenue Forecasts By 29%
10 May 2023 //
FINANCE YAHOO
Cantor Fitzgerald Maintains Prothena (PRTA) Overweight Recommendation
09 May 2023 //
NASDAQ
Prothena to Participate in 2023 Bank of America Healthcare Conference
24 Apr 2023 //
BUSINESSWIRE
Walgreens, Prothena partner to boost enrollment for Alzheimer’s disease trial
17 Apr 2023 //
HEALIO
Prothena teams with Walgreens to accelerate Alzheimer`s trial
13 Apr 2023 //
FIERCE BIOTECH
Prothena Presents New Preclinical Data Supporting Best-in-Class Profile PRX012
31 Mar 2023 //
BUSINESSWIRE
Prothena to Participate in Stifel 2023 Virtual CNS Days
21 Mar 2023 //
PRESS RELEASE
Prothena to Highlight Treatments for Alzheimer’s and Parkinson’s Disease
14 Mar 2023 //
PRESS RELEASE
Prothena to Report Fourth Quarter and Full Year 2022 Financial Results
23 Feb 2023 //
PRESS RELEASE
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Feb 2023 //
BUSINESSWIRE
Prothena unveils volunteer safety data for Alzheimer`s drug in BMS collab
01 Feb 2023 //
ENDPTS
Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005
31 Jan 2023 //
BUSINESSWIRE
Prothena Announces Pricing of Public Offering of 3,250,000 Ordinary Shares
14 Dec 2022 //
PRESS RELEASE
Prothena hopes to raise $180M after Eisai Alzheimer`s data prompted stock surge
14 Dec 2022 //
ENDPTS
Prothena Announces Proposed Public Offering of Ordinary Shares
13 Dec 2022 //
BUSINESSWIRE
Prothena Present Data Demonstrating Consistent Benefit Observed with Birtamimab
12 Dec 2022 //
BUSINESSWIRE
Prothena (PRTA) Earns Milestone Payment From Novo Nordisk
22 Nov 2022 //
PRESS RELEASE
Prothena Announces Achievement of $40 M Clinical Milestone Payment from Nordisk
22 Nov 2022 //
BUSINESSWIRE
Prothena to Present Data on Benefit Observed in Phase 3 Study of Birtamimab
03 Nov 2022 //
PRESS RELEASE
2seventy bio to Present Data from KarMMa-2 Study of Abecma at the 64th ASH
03 Nov 2022 //
BUSINESSWIRE
Prothena Reports Third Quarter 2022 Financial Results and Business Highlights
03 Nov 2022 //
BUSINESSWIRE
Prothena to Report Third Quarter 2022 Financial Results on November 3rd
27 Oct 2022 //
GLOBENEWSWIRE
Prothena Appoints Helen Kim to its Board of Directors
01 Sep 2022 //
GLOBENEWSWIRE
Prothena Announces Appointment of Biotechnology Industry Leader Helen S. Kim
01 Sep 2022 //
GLOBENEWSWIRE
Prothena to Participate in Upcoming Healthcare Conferences
01 Sep 2022 //
GLOBENEWSWIRE
Prothena Reports Second Quarter 2022 Financial Results and Business Highlights
08 Aug 2022 //
GLOBENEWSWIRE
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Aug 2022 //
GLOBENEWSWIRE
Prothena to Report Second Quarter 2022 Financial Results on August 8th
01 Aug 2022 //
GLOBENEWSWIRE
